Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A May 24, 2017
Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy May 23, 2017
Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board May 17, 2017
Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B May 10, 2017
Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors Mar 28, 2017
Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B Mar 21, 2017
Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform Feb 28, 2017
